Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Organisation › Details

SynOx Therapeutics Ltd.

SynOx is a clinical stage biopharmaceutical company. It is a spin out from Celleron Therapeutics Ltd, an oncology company focused on the clinical development of new and innovative therapies to treat cancer. SynOx is developing emactuzumab, a best-in-class CSF1R targeted therapeutic antibody designed to target and deplete tumour-associated macrophages in the tumour tissue. SynOx is led by a team of experts that combines biotech and pharma experience with a successful track record of developing and bringing products to market. It is backed by a strong investor syndicate – HealthCap, Medicxi, Forbion and Gimv. *

 

Period Start 2020-11-19 existent (s-off)
  Today Celleron Therapeutics Ltd.
  Predecessor Celleron Therapeutics Ltd.
Products Industry emactuzumab
  Industry 2 drug development
Person Person La Thangue, Nick (SynOx Therapeutics 202011 CEO)
     
Region Region Dublin
  Country Ireland, Republic of
  City n. a. Dublin
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: SynOx Therapeutics Ltd.. (11/19/20). "Press Release: SynOx Therapeutics Raises €37M in Series A Financing. HealthCap and Medicxi Co-lead, Joined by Forbion and Gimv". Dublin.
     
   
Record changed: 2020-11-19

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for SynOx Therapeutics Ltd.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80




» top